Fact-checked by Grok 2 weeks ago

Anovulation

Anovulation is the absence of ovulation, in which the ovaries fail to release a mature egg during a menstrual cycle, resulting in an anovulatory cycle that prevents fertilization and is a primary cause of female infertility, accounting for approximately 25-30% of cases. Anovulation is classified by the World Health Organization (WHO) into three types based on gonadotropin levels: Type I (hypogonadotropic hypogonadism), Type II (normogonadotropic chronic anovulation, including PCOS), and Type III (hypergonadotropic hypogonadism).^[1]^[2] This condition disrupts the normal hormonal balance of the hypothalamic-pituitary-ovarian axis, leading to irregular or absent menstrual periods known as oligomenorrhea or amenorrhea, respectively.^[3] Common causes include polycystic ovary syndrome (PCOS), which is responsible for approximately 70-90% of anovulatory infertility cases, as well as hypothalamic-pituitary dysfunction, hyperprolactinemia, thyroid disorders, extreme weight changes, excessive exercise, stress, and certain medications.^[1]^[4] In the absence of ovulation, progesterone production is lacking, resulting in unopposed estrogen exposure to the endometrium, which can cause abnormal uterine bleeding characterized by irregular, prolonged, and heavy flow due to endometrial instability.^[5] Symptoms of anovulation often manifest as irregular menstrual cycles, with periods occurring less than eight times per year or varying significantly in length, alongside potential signs such as lack of cervical mucus changes, absence of mid-cycle basal body temperature rise, and in some cases, hirsutism or acne if linked to PCOS.^[1]^[5] While many women with anovulation experience no other overt symptoms, the primary concern is infertility, though it may also increase risks for endometrial hyperplasia if untreated.^[5] Diagnosis typically involves a thorough medical history, physical examination, blood tests to assess hormone levels (such as FSH, LH, prolactin, and thyroid function), and imaging like transvaginal ultrasound to evaluate ovarian morphology and rule out other conditions.^[1]^[5] Treatment focuses on addressing the underlying cause and inducing ovulation when fertility is desired; options include lifestyle modifications like weight management and stress reduction, medications such as letrozole (first-line for PCOS, achieving ovulation in about 80% of cases) or clomiphene citrate, gonadotropins for more resistant cases, and surgical interventions like ovarian drilling for PCOS.^[1]^[6] For non-fertility goals, hormonal therapies like combined oral contraceptives or progestin can regulate bleeding and protect the endometrium.^[5]

Overview

Definition and classification

Anovulation refers to the absence of ovulation, characterized by the failure of a dominant ovarian follicle to develop or release an oocyte during a menstrual cycle, resulting in anovulatory cycles without the typical mid-cycle surge in luteinizing hormone.^[7] This condition disrupts the normal reproductive process, as no corpus luteum forms to produce progesterone, often leading to irregular or absent menstrual bleeding.^[8] Anovulation is distinct from oligo-ovulation, which involves infrequent or irregular ovulation, typically defined as menstrual cycles longer than 36 days or fewer than eight ovulatory cycles per year, whereas anovulation represents a complete lack of ovulation in affected cycles.^[9] In clinical practice, this differentiation is important for assessing ovulatory function, with anovulation implying a more profound disruption in follicular maturation compared to the sporadic ovulation seen in oligo-ovulation.^[8] The World Health Organization (WHO) classifies anovulatory disorders into three main types based on gonadotropin and estrogen levels, providing a framework for understanding the underlying endocrine imbalances; this system, introduced in 1973, has been supplemented by the 2022 FIGO HyPO-P classification (hypothalamic, pituitary, ovarian, PCOS), which offers a contemporary organ-based categorization.^[8]^[10] Type I encompasses hypogonadotropic hypogonadism, marked by low levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol due to hypothalamic-pituitary dysfunction.^[8] Type II involves normogonadotropic anovulation, with normal or fluctuating gonadotropin levels and adequate estrogen production, as seen in conditions like polycystic ovary syndrome (PCOS). Type III denotes hypergonadotropic hypogonadism, characterized by elevated FSH and LH with low estradiol, often resulting from ovarian failure such as primary ovarian insufficiency (POI).^[8]

Epidemiology and prevalence

Anovulation affects approximately 5% to 10% of women of reproductive age worldwide, with polycystic ovary syndrome (PCOS) accounting for the majority of chronic cases and exhibiting a prevalence of 4% to 8% based on NIH/NICHD criteria or 6–13% per broader WHO estimates as of 2025.^[11]^[12] Sporadic anovulatory cycles occur in up to 15% of reproductive years overall, though chronic anovulation is less common at around 6% to 10% in women aged 19 to 39 with hyperandrogenic conditions like PCOS.^[13]^[5] Anovulation is a leading contributor to infertility, responsible for 25% to 30% of cases in women seeking treatment, with PCOS comprising 80% to 85% of those anovulatory infertility instances.^[14]^[2] Demographic patterns show higher rates in specific groups; for instance, up to 95% of abnormal uterine bleeding in adolescents stems from anovulatory cycles due to hypothalamic-pituitary-ovarian axis immaturity, with anovulation affecting 50% or more of cycles in the first postmenarcheal year, declining to about 20% by the fifth year.^[15]^[16] Obesity significantly elevates risk, with women having a BMI greater than 30 kg/m² facing a 2- to 3-fold increased likelihood of anovulation compared to those with normal weight, independent of androgen levels.^[17]^[18] Ethnic variations are notable, particularly for PCOS-related anovulation, which shows higher prevalence and earlier onset in South Asian populations, often accompanied by greater metabolic syndrome risk than in White or East Asian groups.^[19]^[20] Recent trends indicate a rising incidence of anovulation, driven by global obesity increases—projected to affect over 1.5 billion adults by 2035—and environmental factors like endocrine disruptors, with post-2020 data from the COVID-19 era showing elevated anovulatory cycles in up to 7.7% of tracked menstruations amid lifestyle disruptions.^[21]^[22]^[23] Age-related risks intensify after 35, as fertility declines accelerate due to reduced ovulatory frequency, compounded by lifestyle influences such as chronic stress and poor diet, which disrupt hormonal balance and elevate oxidative stress.^[24]^[25]

Pathophysiology

Normal ovulatory cycle

The normal ovulatory menstrual cycle is a finely tuned physiological process regulated by the hypothalamic-pituitary-ovarian (HPO) axis, typically lasting an average of 28 days with a normal range of 21 to 35 days.^[26] This variability primarily arises from fluctuations in the follicular phase duration, while the luteal phase remains relatively fixed at about 14 days, influenced by intricate negative and positive feedback loops involving hormones such as estradiol, progesterone, and inhibin B.^[27] The hypothalamus plays a central role by secreting gonadotropin-releasing hormone (GnRH) in a pulsatile manner, which stimulates the anterior pituitary to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH).^[26] These pituitary hormones, in turn, act on the ovaries to drive folliculogenesis, the development of ovarian follicles, ensuring coordinated preparation for potential fertilization.^[27] The follicular phase begins on the first day of menstruation and lasts until ovulation, marked by an initial rise in FSH levels during the late luteal phase of the previous cycle.^[26] This FSH surge recruits a cohort of primordial follicles in the ovaries, stimulating their growth into primary, secondary, and eventually antral follicles, with one dominant follicle typically selected around days 5 to 7.^[27] As the dominant follicle matures, it produces increasing amounts of estradiol from granulosa cells, which exerts negative feedback on the pituitary to suppress further FSH secretion, thereby inhibiting the growth of subordinate follicles and promoting selection of the leader.^[26] Follicle growth accelerates, reaching 18 to 29 mm in diameter (average 23.6 mm) by the end of this phase, driven by both FSH and rising LH levels that enhance receptor sensitivity in the dominant follicle.^[27] Ovulation represents the culminating event of the follicular phase, occurring approximately on day 14 in a standard 28-day cycle, triggered by a mid-cycle surge in LH.^[26] This LH surge, a 10-fold increase in amplitude, is induced by positive feedback from sustained high estradiol levels (above 200 pg/mL for about 50 hours) from the preovulatory follicle, prompting the resumption of meiosis in the oocyte and enzymatic degradation of the follicular wall.^[27] The oocyte is released into the fallopian tube 36 to 44 hours after the onset of the LH surge, with the fertile window spanning 24 to 36 hours post-LH peak, during which fertilization can occur if sperm are present.^[26] Following ovulation, the luteal phase ensues as the ruptured follicle transforms into the corpus luteum under LH stimulation, which becomes vascularized and actively secretes progesterone to prepare the endometrium for implantation.^[27] Progesterone levels peak around 8 to 9 days post-ovulation, maintaining endometrial secretory changes and inhibiting further GnRH pulses to prevent additional ovulations.^[26] If pregnancy does not occur, the corpus luteum undergoes luteolysis after approximately 14 days, leading to a decline in progesterone and estradiol, which removes endometrial support and initiates menstruation to restart the cycle.^[27]

Mechanisms leading to anovulation

Anovulation arises from disruptions at multiple levels of the hypothalamic-pituitary-ovarian (HPO) axis, preventing the coordinated hormonal signals necessary for follicular maturation and ovum release. Central defects primarily involve impaired gonadotropin-releasing hormone (GnRH) pulsatility from the hypothalamus, which fails to stimulate adequate secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary. This reduction in pulsatile GnRH leads to chronically low levels of FSH and LH, impairing follicular recruitment and growth, as GnRH pulses are essential for maintaining gonadotropin synthesis and release.^[28]^[29] Peripheral mechanisms manifest as follicle arrest, where antral follicles develop to small sizes (typically 5-10 mm) but fail to progress to dominance, resulting in multiple immature follicles without selection of a preovulatory follicle. This arrest often accompanies a failure of the mid-cycle LH surge, which is required to trigger final oocyte maturation and ovulation; without sufficient estrogen priming or HPO axis integrity, the surge does not occur, halting ovulatory progression.^[28]^[30] Feedback dysregulation contributes significantly, particularly through altered negative and positive feedback loops in the HPO axis. Insulin resistance, common in conditions like polycystic ovary syndrome, amplifies ovarian androgen production by decreasing sex hormone-binding globulin (SHBG) levels and directly stimulating theca cell androgen synthesis, which suppresses follicular estrogen output and disrupts the estrogen-mediated positive feedback needed for the LH surge. Additionally, estrogen deficiency at the follicular stage can prevent the requisite surge by failing to sensitize the pituitary to GnRH, perpetuating anovulatory cycles.^[31]^[28] At the cellular level, anovulation involves accelerated follicular atresia, where non-dominant follicles undergo programmed cell death via apoptosis triggered by pro-apoptotic signals such as Fas ligand and caspase activation in granulosa cells, leading to follicular degeneration before ovulation. Anti-Müllerian hormone (AMH), produced by granulosa cells of small antral follicles, plays a key inhibitory role by suppressing FSH sensitivity and primordial follicle recruitment, resulting in excessive follicular inhibition and stalled development when AMH levels are elevated, as seen in hyperandrogenic states.^[32]^[33]^[34]

Clinical presentation

Signs and symptoms

Anovulation primarily manifests through disruptions in menstrual patterns, as the absence of ovulation leads to irregular or absent hormonal fluctuations that normally regulate the cycle. Common presentations include oligomenorrhea, characterized by menstrual cycles longer than 35 days, and amenorrhea, defined as the absence of menstrual bleeding for more than 90 days in the absence of pregnancy.^[35] Additionally, individuals may experience irregular uterine bleeding, which is often unpredictable, heavy, or prolonged due to unopposed estrogen stimulation of the endometrium without the stabilizing effect of progesterone from a corpus luteum.^[5] Infertility is a frequent symptom, serving as the primary complaint for many seeking medical attention, as anovulation prevents the release of an egg necessary for conception.^[14] In cases associated with androgen excess, such as those involving elevated androgens, additional symptoms like acne and hirsutism may occur, reflecting hyperandrogenic influences on skin and hair follicles.^[35] Mild pelvic pain or cramping can also arise during bleeding episodes in anovulatory cycles, comparable in intensity to pain in ovulatory cycles.^[36] Systemic effects from prolonged anovulation may include weight gain and fatigue, potentially stemming from hormonal imbalances such as unopposed estrogen exposure.^[14] Notably, the absence of ovulation eliminates mittelschmerz, the mid-cycle pain typically experienced during egg release. Symptoms often develop insidiously during the reproductive years, though they can onset more acutely in response to stressors like excessive exercise or weight changes.^[37]

Associated conditions

Anovulation is a leading cause of female infertility, accounting for approximately 25% of infertility diagnoses among reproductive-age women.^[38] Chronic anovulation results in the absence of ovulation, preventing conception and contributing to subfertility in affected individuals. Polycystic ovary syndrome (PCOS), the most common etiology, underlies about 70% of anovulatory infertility cases.^[38] Prolonged anovulation exposes the endometrium to unopposed estrogen stimulation, increasing the risk of endometrial hyperplasia.^[39] This condition arises from irregular or absent progesterone production, leading to endometrial proliferation without the balancing effects of the luteal phase. Women with chronic anovulation, particularly those with PCOS, face a heightened risk of developing hyperplasia, which can progress to more serious pathology if untreated.^[39] In the metabolic domain, anovulation, especially in PCOS, is associated with a 3.45-fold increased risk of type 2 diabetes mellitus compared to women without the condition.^[40] This elevated risk stems from insulin resistance, a hallmark of PCOS-related anovulation, which impairs glucose metabolism and promotes hyperglycemia. Obesity exhibits a bidirectional relationship with anovulation; excess adiposity exacerbates hyperandrogenemia and ovulatory dysfunction, while anovulatory states like PCOS contribute to weight gain through hormonal imbalances and metabolic dysregulation.^[41] Thyroid disorders frequently co-occur with anovulation, as both hyperthyroidism and hypothyroidism disrupt ovulatory function. In hyperthyroidism, menstrual cycle disturbances occur in approximately 21.5% of patients, and anovulatory cycles are very common among those affected.^[42] Hypothyroidism similarly impairs ovulation, often leading to reduced fertility. Eating disorders, such as anorexia nervosa, are linked to anovulation via malnutrition and low body weight, which suppress hypothalamic-pituitary-ovarian signaling and cause functional hypothalamic amenorrhea.^[43] Hypoestrogenism from chronic anovulation contributes to bone density loss, with affected women experiencing spinal bone mineral reductions of approximately 4.2% per year.^[44] Long-term, chronic anovulation elevates cardiovascular disease risk, particularly in PCOS, where metabolic syndrome components like dyslipidemia and hypertension cluster.^[45] A 2023 study indicates that PCOS-associated anovulation heightens the risk of premalignant and malignant endometrial polyps in premenopausal women, with an adjusted odds ratio of 2.75.^[46] This underscores the need for vigilant endometrial surveillance in chronic cases.^[46]

Etiology

Hypothalamic-pituitary-ovarian axis disorders

Disorders of the hypothalamic-pituitary-ovarian (HPO) axis represent a significant category of anovulation etiology, accounting for approximately 10% of cases, characterized by disruptions in gonadotropin-releasing hormone (GnRH) secretion or pituitary gonadotropin production that impair follicular development and ovulation.^[47] These central defects lead to hypogonadotropic hypogonadism, with low levels of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) serving as a diagnostic hallmark, often confirmed through laboratory evaluation.^[47] Polycystic ovary syndrome (PCOS) is the most common HPO axis disorder causing anovulation, responsible for up to 70% of anovulatory infertility cases. It involves chronic anovulation with hyperandrogenism and polycystic ovarian morphology, driven by insulin resistance, elevated LH/FSH ratios, and impaired follicular maturation due to disrupted GnRH pulsatility and ovarian steroidogenesis.^[3] Hypothalamic causes primarily involve functional hypothalamic amenorrhea (FHA), a reversible condition triggered by factors such as psychological stress, excessive exercise, or low body weight, which suppress GnRH pulsatility from the hypothalamus.^[47] FHA affects an estimated 1-2% of female athletes, though prevalence can reach 20-30% in certain high-intensity sports like endurance running or ballet, due to energy deficits and chronic stress disrupting the HPO axis.^[48] FHA cases often resolve with lifestyle interventions, such as weight restoration and reduced exercise intensity, highlighting the adaptive nature of this suppression.^[49] Pituitary disorders contributing to anovulation include tumors such as prolactinomas, which are adenomas secreting excess prolactin; hyperprolactinemia accounts for 10-20% of cases of ovulatory dysfunction through inhibition of GnRH, with prolactinomas being the most common pathological cause.^[50]^[51] Another key pituitary issue is Sheehan's syndrome, a postpartum condition resulting from ischemic necrosis of the pituitary gland due to severe hemorrhage during delivery, which impairs gonadotropin secretion and causes chronic anovulation in affected individuals.^[52] Axis-wide disruptions encompass congenital conditions like Kallmann syndrome, a genetic form of GnRH deficiency arising from failed migration of GnRH-producing neurons during embryonic development, resulting in isolated hypogonadotropic hypogonadism and lifelong anovulation without intervention.^[53]

Ovarian and adrenal causes

Primary ovarian insufficiency (POI), also known as premature ovarian failure, is a leading ovarian cause of anovulation, characterized by the loss of ovarian function before age 40, resulting in amenorrhea for at least four months, elevated follicle-stimulating hormone (FSH) levels greater than 40 IU/L, and low estradiol concentrations.^[54] This condition affects approximately 1% to 2% of women under 40 years old, with a rarer occurrence of 0.1% in those under 30.^[54] POI leads to anovulation through mechanisms such as accelerated follicle depletion or dysfunction, where the ovarian reserve diminishes prematurely, disrupting follicular development and ovulation while reducing negative feedback on the pituitary gland, thereby elevating FSH levels.^[54] Genetic factors, including Turner syndrome and Fragile X premutations (59-199 CGG repeats in the FMR1 gene), account for up to 20% of cases, while autoimmune etiologies, such as associations with Addison's disease (10-20% overlap) or thyroid autoimmunity (14-27%), contribute to ovarian inflammation and follicular atresia.^[54] Adrenal causes of anovulation primarily stem from congenital adrenal hyperplasia (CAH), an autosomal recessive disorder resulting from enzymatic defects in cortisol synthesis, leading to adrenocorticotropic hormone (ACTH) overstimulation and excess androgen production.^[55] The most common form, 21-hydroxylase deficiency, has a global incidence of 1 in 15,000 to 20,000 live births for the classic variant, which often presents with virilization and menstrual irregularities.^[55] In females, the resultant hyperandrogenism disrupts ovarian function by inhibiting follicular maturation and ovulation, causing anovulatory cycles and oligo- or amenorrhea in 30% to 60% of untreated cases, frequently mimicking polycystic ovary syndrome.^[55] Nonclassic CAH, with a higher prevalence of 1 in 1,000, similarly elevates adrenal androgens, contributing to chronic anovulation through interference with gonadotropin signaling and ovarian steroidogenesis.^[55] Resistant ovary syndrome (ROS), a rare combined ovarian-adrenal influenced condition, features hypergonadotropic hypogonadism with normal ovarian follicle reserves but unresponsiveness to gonadotropins, leading to primary or secondary amenorrhea before age 30.^[56] Despite normal anti-Müllerian hormone (AMH) and inhibin B levels indicating preserved follicles, anovulation occurs due to stalled follicular development at the primordial or primary stage, often from inactivating mutations in the FSH receptor (FSHR) gene or autoantibodies targeting FSHR.^[56] Additional mechanisms include deficiencies in FSH growth factors like GDF9 or BMP15, or abnormal gonadotropin signaling pathways, rendering follicles insensitive to stimulation and preventing ovulation without depleting the ovarian pool.^[56] This contrasts with POI by maintaining normal hormone markers of reserve while exhibiting elevated FSH due to failed feedback, highlighting a post-receptor defect in ovarian responsiveness.^[56]

Other endocrine and iatrogenic factors

Hyperprolactinemia, characterized by elevated serum prolactin levels exceeding 25 ng/mL, disrupts the reproductive axis by suppressing the pulsatile release of gonadotropin-releasing hormone (GnRH) from the hypothalamus, which in turn reduces luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, leading to anovulation.^[57]^[58] This condition can arise from various causes, including prolactin-secreting pituitary adenomas, but drug-induced hyperprolactinemia is notable, particularly with antipsychotic medications that block dopamine D2 receptors; such agents are associated with hyperprolactinemia in approximately 40-70% of treated women, contributing to menstrual irregularities and infertility.^[59]^[60] Thyroid dysfunction, encompassing both hypothyroidism and hyperthyroidism, interferes with gonadotropin secretion and ovarian steroidogenesis, often resulting in anovulatory cycles and contributing to roughly 5-10% of cases of anovulatory infertility.^[61] In hypothyroidism, reduced thyroid hormone levels elevate thyrotropin-releasing hormone, which stimulates prolactin release and indirectly impairs GnRH pulsatility; hyperthyroidism, conversely, accelerates ovarian metabolism and disrupts follicular development through excessive gonadotropin modulation.^[62]^[63] Cushing's syndrome, marked by chronic cortisol excess, induces anovulation by elevating glucocorticoids that suppress GnRH and LH pulsatility, while also promoting hyperandrogenism and central obesity that further impair ovarian function.^[64] Iatrogenic factors, particularly those from cancer treatments, frequently cause anovulation through direct gonadal toxicity. Alkylating agent chemotherapy, such as cyclophosphamide, poses a 30-60% risk of premature ovarian insufficiency (POI) by damaging primordial follicles via DNA alkylation and accelerated atresia, with the likelihood increasing with cumulative dose and patient age.^[65]^[66] Pelvic radiation therapy similarly induces anovulation and POI by causing vascular damage and follicular apoptosis in the ovary, with risks exceeding 90% at doses over 20 Gy. Hormonal contraceptives, including combined oral pills and progestin-only methods, intentionally suppress ovulation by inhibiting the mid-cycle LH surge through negative feedback on the hypothalamic-pituitary axis, leading to anovulatory cycles during use.^[67] Recent investigations into vaccine-related effects have identified rare instances of transient anovulation linked to COVID-19 vaccination, potentially due to immune-mediated disruptions in ovarian granulosa cell function and subtle alterations in menstrual cyclicity, as noted in 2024 studies and guidelines emphasizing the temporary and uncommon nature of such events.^[68]^[69]

Diagnosis

Medical history and physical examination

The initial clinical evaluation of suspected anovulation begins with a detailed medical history to identify patterns suggestive of ovulatory dysfunction. Key elements include assessing menstrual cycle length and bleeding characteristics, such as oligomenorrhea (fewer than nine menses per year) or amenorrhea (absence of menses for three months or more in women with previously regular cycles), which are hallmark indicators of anovulation.^[70] Inquiries should also cover fertility attempts, including duration of unprotected intercourse without conception, as chronic anovulation is a leading cause of infertility.^[71] Additional history focuses on weight changes, such as recent gain or loss exceeding 10% of body weight, which can disrupt hypothalamic function; excessive stress or intense exercise levels, often linked to functional hypothalamic amenorrhea; and medication use, including hormonal contraceptives, antipsychotics, or antidepressants that may suppress ovulation.^[72] Family history of endocrine disorders, such as polycystic ovary syndrome (PCOS) or premature ovarian insufficiency, should be elicited to guide suspicion of genetic etiologies.^[73] Symptom inquiry further refines the differential diagnosis by probing for manifestations of underlying endocrine imbalances. Patients should be questioned about signs of hyperandrogenism, including hirsutism (excessive hair growth in androgen-sensitive areas), acne, and androgenic alopecia (female-pattern hair loss).^[73] The presence of galactorrhea, or spontaneous nipple discharge, warrants specific attention as it may indicate hyperprolactinemia from a pituitary adenoma.^[71] Headaches, visual disturbances, or symptoms of pituitary dysfunction, such as fatigue or polyuria, should also be explored to identify central causes.^[70] The physical examination complements the history by providing objective evidence of systemic involvement. Body mass index (BMI) is calculated to evaluate nutritional status, with obesity (BMI ≥30 kg/m²) commonly associated with PCOS-related anovulation and low BMI (<18.5 kg/m²) with hypothalamic suppression.^[73] Signs of androgen excess are systematically assessed, including acne severity and alopecia patterns, while hirsutism is quantified using the modified Ferriman-Gallwey scoring system, which evaluates hair growth at nine body sites (a score ≥8 suggests clinical hyperandrogenism, adjusted for ethnicity).^[73] A pelvic examination is performed to detect ovarian masses, uterine abnormalities, or signs of estrogen deficiency, such as vaginal atrophy. Thyroid palpation checks for goiter or nodularity indicative of dysfunction. Breast examination screens for galactorrhea or asymmetry.^[70] Red flags identified during evaluation necessitate urgent referral. Galactorrhea combined with headaches or visual changes raises concern for prolactinoma and requires neuroimaging. Rapid-onset virilization, such as clitoromegaly or deepening voice, signals possible androgen-secreting tumors. A family history of early menopause or genetic syndromes, like fragile X premutation, prompts consideration of inherited ovarian causes.^[71]

Laboratory and imaging investigations

Laboratory and imaging investigations play a crucial role in confirming anovulation and identifying its underlying etiology by assessing hormonal profiles and structural abnormalities in the reproductive system. Initial hormone assays typically include measurements of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, and progesterone, which help evaluate the hypothalamic-pituitary-ovarian axis function.^[74] Serum FSH and LH levels, often measured on day 3 of the menstrual cycle, provide insights into ovarian reserve and potential disorders like polycystic ovary syndrome (PCOS), where an elevated LH/FSH ratio greater than 2:1 may be observed.^[74] Estradiol levels, assessed alongside FSH, aid in detecting premature ovarian insufficiency if elevated on cycle day 3, while a low or absent mid-cycle LH surge indicates failure of ovulation.^[75] Progesterone measurement around day 21 of a 28-day cycle, with levels below 3 ng/mL suggesting anovulation due to lack of corpus luteum formation, serves as a direct confirmatory test for ovulatory dysfunction.^[76] Additional laboratory tests target potential endocrine contributors to anovulation. Prolactin levels are evaluated to rule out hyperprolactinemia, which can suppress gonadotropin-releasing hormone and lead to ovulatory failure.^[77] Thyroid-stimulating hormone (TSH) testing excludes hypothyroidism, a common reversible cause of anovulation through its impact on gonadotropin secretion.^[78] In suspected hyperandrogenic states like PCOS, serum testosterone is measured, often elevated alongside anti-Müllerian hormone (AMH), which is typically raised in PCOS due to increased antral follicle count reflecting follicular arrest.^[79] For nonclassical congenital adrenal hyperplasia (CAH), 17-hydroxyprogesterone levels are assessed, with elevations prompting further evaluation to differentiate from other anovulatory causes.^[80] Imaging modalities provide visual confirmation of anovulatory patterns and associated pathologies. Transvaginal ultrasound is the primary tool for monitoring ovarian follicle development, where the absence of a dominant follicle greater than 18 mm or lack of corpus luteum formation supports an anovulatory diagnosis; it also reveals thickened endometrial lining, often greater than 8 mm, due to unopposed estrogen effects.^[74] In cases of suspected PCOS, ultrasound may show 20 or more small follicles (2-5 mm) in at least one ovary or ovarian volume greater than 10 mL.^[73] For hypothalamic-pituitary disorders, such as prolactinomas causing anovulation, magnetic resonance imaging (MRI) of the pituitary gland is recommended to detect adenomas, offering superior soft-tissue resolution compared to computed tomography.^[81] Advanced testing, such as the clomiphene citrate challenge test (CCCT), assesses ovarian responsiveness in ambiguous cases. This involves measuring FSH on cycle day 3, administering clomiphene citrate (100 mg daily) from days 5-9, and remeasuring FSH on day 10; an elevated day 10 FSH above 10-15 mIU/mL indicates diminished ovarian reserve contributing to anovulation.^[75] Recent guidelines emphasize AMH as a reliable, cycle-independent marker of ovarian reserve over antral follicle count (AFC) in some contexts, particularly for predicting response to stimulation in anovulatory patients, due to its reproducibility and association with primordial follicle pool.^[82]

Management

Lifestyle and non-pharmacological interventions

Lifestyle modifications play a central role in managing anovulation, particularly in conditions like polycystic ovary syndrome (PCOS) and hypothalamic amenorrhea, by addressing underlying factors such as obesity, insulin resistance, and stress without relying on medications. Weight management is a cornerstone intervention, especially for overweight or obese women with PCOS, where even modest reductions can restore ovulatory function. Clinical guidelines recommend a weight loss of 5-10% through calorie-restricted diets and increased physical activity to reverse anovulatory status and enhance natural conception rates.^[83] In practice, hypocaloric dietary protocols promoting a negative energy balance have been shown to induce sporadic ovulation across a range of patients with PCOS and obesity, though the exact threshold for ovulation resumption varies individually.^[84] For women with hypothalamic amenorrhea, often linked to excessive exercise or psychological stress, interventions focus on balancing energy availability and reducing stressors to normalize the hypothalamic-pituitary-ovarian axis. Reducing vigorous exercise intensity while maintaining moderate activity—such as 150 minutes per week of aerobic exercise—helps prevent energy deficits that suppress ovulation.^[85] Concurrently, stress reduction techniques like cognitive behavioral therapy (CBT), delivered over 16-20 sessions, address maladaptive coping and eating patterns, leading to restoration of ovulatory function in cases driven by psychological factors.^[86] While success rates depend on adherence and individual factors, lifestyle adjustments including these elements have enabled menstrual recovery in subsets of patients, with average timelines of 17-19 months reported in observational data.^[87] Dietary strategies emphasizing low-glycemic index (GI) foods further support ovulation by improving insulin sensitivity, a key contributor to anovulation in PCOS. Randomized trials demonstrate that low-GI diets enhance menstrual regularity and ovulation rates by approximately 18% in women with insulin resistance, independent of major weight changes.^[88] These diets prioritize whole grains, legumes, and non-starchy vegetables to minimize blood glucose spikes and hyperinsulinemia. Complementing this, myo-inositol supplementation, typically at 4 g daily, acts as an insulin sensitizer and has improved ovulation rates to 70% in PCOS patients compared to 21% in controls across clinical trials.^[89] Acupuncture represents another non-pharmacological option, particularly for PCOS-related anovulation, with evidence from systematic reviews supporting its role in modulating hormonal pathways. A 2025 meta-analysis of 43 randomized controlled trials involving over 4,800 participants found that acupuncture alone increased ovulation rates with a relative risk of 1.15 compared to sham treatments, and up to 1.27 when combined with herbal medicine versus pharmacotherapy alone. Optimal protocols involve 3-4 sessions per week for 24 weeks, targeting multiple acupoints to promote endocrine balance and endometrial receptivity. These findings indicate acupuncture can induce ovulation in 15-27% more cases than controls, offering a viable adjunct for fertility restoration.^[90]

Pharmacological treatments by cause

For women not seeking fertility, management of anovulation often involves hormonal therapies to regulate menstrual cycles and mitigate risks like endometrial hyperplasia from unopposed estrogen exposure. Combined oral contraceptives (COCs), typically containing ethinyl estradiol 20-35 μg with a progestin, suppress ovarian activity, induce regular withdrawal bleeding, and provide endometrial protection; they are first-line for PCOS and other anovulatory conditions without fertility goals. Cyclic progestin therapy, such as medroxyprogesterone acetate 10 mg daily for 10-14 days every 1-3 months, can also be used to trigger withdrawal bleeds and reduce hyperplasia risk in amenorrheic patients.^[5]^[91] Pharmacological treatments for anovulation are tailored to the underlying etiology to restore ovulatory function where possible, with efficacy varying by condition. In polycystic ovary syndrome (PCOS), the most common cause, first-line options include selective estrogen receptor modulators and aromatase inhibitors to promote follicle development. Clomiphene citrate, administered at 50-150 mg daily for 5 days starting on cycle day 3-5, induces ovulation in 60-85% of anovulatory women with PCOS by blocking estrogen feedback at the hypothalamus, leading to increased gonadotropin secretion.^[92] Letrozole, an aromatase inhibitor given at 2.5-7.5 mg daily for 5 days, has demonstrated superior outcomes to clomiphene in a 2023 meta-analysis of randomized trials, with higher ovulation rates and a live birth rate of approximately 27% per cycle in PCOS patients.^[93] For hypogonadotropic hypogonadism, including hypothalamic amenorrhea (HA), treatments aim to mimic physiologic gonadotropin pulses or directly stimulate the ovaries. Pulsatile gonadotropin-releasing hormone (GnRH) therapy, delivered via a subcutaneous pump at 5-20 μg every 90-120 minutes, achieves ovulation rates of 89-96% per cycle by restoring endogenous follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion, with monofollicular development in up to 75% of cycles.^[94] Alternatively, exogenous gonadotropins such as human menopausal gonadotropin (hMG), containing both FSH and LH activity, are administered at low doses of 75-150 IU subcutaneously 2-3 times weekly, yielding ovulation in about 84-90% of HA cases while minimizing multiple gestation risks.^[95] In premature ovarian insufficiency (POI), pharmacological options focus on symptom management rather than ovulation induction, as ovarian reserve is depleted. Estrogen-progesterone replacement therapy, typically oral conjugated estrogens 0.625-1.25 mg daily combined with medroxyprogesterone acetate 5-10 mg for 10-14 days monthly, alleviates hypoestrogenic symptoms like hot flashes and bone loss but does not restore ovulatory function.^[96] This approach is recommended until age 50-51 to mimic natural gonadal function, though fertility requires donor oocytes.^[97] Hyperprolactinemia-induced anovulation responds well to dopamine agonists that suppress prolactin secretion and normalize the hypothalamic-pituitary-ovarian axis. Cabergoline, dosed at 0.5 mg orally once or twice weekly, normalizes serum prolactin levels in over 90% of patients with prolactinomas or idiopathic hyperprolactinemia, often restoring ovulatory cycles within 1-3 months.^[98] For thyroid-related causes, levothyroxine replacement at 1.6-1.8 μg/kg daily corrects hypothyroidism-associated anovulation by normalizing thyroid-stimulating hormone and reversing ovulatory dysfunction in most cases.^[99] In hyperthyroidism, antithyroid drugs like methimazole 10-30 mg daily or propylthiouracil 300-600 mg daily achieve euthyroidism, thereby resuming regular ovulation without direct ovarian effects.^[100]

Fertility-focused options

For women with anovulatory infertility seeking pregnancy, ovulation induction is closely monitored through serial transvaginal ultrasounds to assess follicular development, typically starting from day 5-7 of stimulation and repeated every 1-3 days to track follicle size and number, minimizing risks like ovarian hyperstimulation syndrome (OHSS).^[95] When a dominant follicle reaches 18-20 mm, final oocyte maturation is triggered with human chorionic gonadotropin (hCG) at a dose of 10,000 IU intramuscularly, inducing ovulation approximately 36-40 hours later to optimize timing for conception.^[95]^[101] Assisted reproductive technologies enhance success following ovulation induction. Intrauterine insemination (IUI) involves placing prepared sperm into the uterus 24-36 hours post-hCG trigger, yielding pregnancy rates of about 15% per cycle in anovulatory women, particularly those with polycystic ovary syndrome (PCOS).^[95] For cases resistant to induction or with additional factors like tubal issues, in vitro fertilization (IVF) is recommended, involving controlled ovarian stimulation, oocyte retrieval, and embryo transfer, with live birth rates of 30-40% per cycle in women under 35 years.^[102] Surgical interventions, such as laparoscopic ovarian drilling (LOD) for PCOS, create small perforations in the ovarian stroma to reduce androgen production and restore ovulation in approximately 50% of clomiphene-resistant cases, though its use is declining per 2023 international guidelines favoring pharmacological options due to potential impacts on ovarian reserve.^[73]^[103] In premature ovarian insufficiency (POI), where endogenous oocyte production is severely limited, oocyte donation offers a viable path to parenthood, with live birth rates exceeding 50% per transfer using donor eggs via IVF, as supported by 2024 guidelines emphasizing its established efficacy.^[97]^[104]

Prognosis and complications

Long-term outcomes

Anovulation arising from functional causes, such as hypothalamic amenorrhea due to excessive exercise, stress, or weight loss, is often reversible upon addressing the underlying factors. In a long-term follow-up study of women with functional hypothalamic amenorrhea, approximately 71% recovered menstrual cycling over an average of 8 years, with higher rates observed among those who restored positive energy balance or received appropriate hormone replacement therapy.^[105] Similarly, weight-related anovulation in conditions like polycystic ovary syndrome (PCOS) shows high reversibility with sustained lifestyle modifications, where even modest weight reduction of 5-10% can restore ovulatory function in many cases.^[106] In contrast, anovulation associated with premature ovarian insufficiency (POI) tends to be more permanent, though spontaneous remission occurs in a subset of patients. Studies indicate that only 5-10% of women with POI experience a sustained return of ovarian function, highlighting the condition's largely irreversible nature in most cases.^[107] Treatment for anovulation generally yields favorable fertility outcomes, with cumulative conception rates of 70-80% achievable through ovulation induction protocols, such as clomiphene citrate or letrozole, followed by gonadotropins if needed.^[108] However, advancing maternal age significantly diminishes these prospects; for women over 35 years, success rates per cycle often drop to 10-20%, reflecting declines in oocyte quality and quantity.^[106] Recurrence of anovulation is particularly prevalent in PCOS when initial improvements from weight loss are not maintained. Early intervention in adolescents further enhances long-term resolution, with studies showing improved ovulatory regularity through timely lifestyle and pharmacological strategies.^[109] The 2023 international evidence-based guideline for PCOS emphasizes multidisciplinary approaches to improve long-term health outcomes.^[110]

Potential health risks

Persistent anovulation leads to unopposed estrogen exposure on the endometrium, promoting endometrial hyperplasia and substantially elevating the risk of endometrial cancer. Women with chronic anovulation, particularly those associated with polycystic ovary syndrome (PCOS), face a 2- to 3-fold increased risk of developing endometrial cancer compared to ovulatory women, primarily due to the absence of progesterone's protective effects.^[111] This risk arises from prolonged estrogen stimulation without cyclical shedding, which can progress to atypical hyperplasia and adenocarcinoma over time.^[112] Hypoestrogenism in anovulatory states, often resulting from hypothalamic-pituitary-ovarian axis disruptions, contributes to accelerated bone loss and osteoporosis. Women experiencing chronic anovulation demonstrate bone mineral density (BMD) reductions of approximately 1-2% per year at the spine, comparable to postmenopausal rates, due to diminished estrogen-mediated bone protection.^[113] This hypoestrogenic environment increases fracture risk, particularly in the absence of compensatory interventions.^[114] Metabolically, anovulation exacerbates insulin resistance, which progresses to type 2 diabetes mellitus in susceptible individuals, especially within PCOS contexts. The underlying hyperinsulinemia and impaired glucose metabolism heighten diabetes risk by promoting beta-cell dysfunction and pancreatic exhaustion over years.^[115] Cardiovascular disease (CVD) risk is similarly amplified, with women experiencing anovulation via PCOS showing a 1.5- to 2-fold higher incidence of CVD events, driven by endothelial dysfunction, dyslipidemia, and hypertension.^[116] Psychologically, the infertility stemming from anovulation correlates with elevated depression rates, affecting approximately 30% of affected women through chronic stress and self-esteem impacts. Recent 2024 research further links persistent anovulation, as seen in premature ovarian insufficiency, to a 2.6-fold increased prevalence of autoimmune disorders, potentially via shared inflammatory pathways affecting ovarian function.^[117]^[118] To mitigate gynecologic complications, endometrial biopsy may be recommended for high-risk women, such as those over 45 years or with additional risk factors like obesity and prolonged anovulation, per current ACOG guidelines, to enable early detection of hyperplasia or malignancy.^[119]

References

[1]
What Is Anovulation?
### Summary of Anovulation from WebMD
[2]
Anovulation and ovulation induction - PMC - PubMed Central
Anovulation can sometimes be treated with medical or surgical induction, but it is the cause of the anovulation that will determine whether ovulation induction ...
[3]
Anovulatory Bleeding - StatPearls - NCBI Bookshelf
Mar 23, 2025 · Anovulatory bleeding is a type of abnormal uterine bleeding (AUB) that occurs when ovulation fails to occur during the menstrual cycle.
[4]
Evaluation of Infertility, Ovulation Induction and Assisted Reproduction
Apr 12, 2016 · Modern gynecologists wrote about infertility in the mid-20th century as a descriptive state induced by a certain personality type of the woman ...
[5]
The FIGO Ovulatory Disorders Classification System - PMC - NIH
Furthermore, anovulation is only one extreme of ovulatory dysfunction that includes a spectrum of manifestations that range from isolated episodes to ...
[6]
Anovulation - UF Health
Nov 8, 2022 · Anovulation and oligo-ovulation are typically associated with cessation of regular menstrual cycles or increased length between tow menstrual periods greater ...
[7]
Epidemiology, diagnosis, and management of polycystic ovary ...
Prevalence estimates for PCOS, as defined by the NIH/NICHD criteria, indicate that PCOS is a common endocrinopathy affecting 4%–8% of women of reproductive age.
[8]
Anovulation: epidemiology - News-Medical
Anovulation may occur in up to 15% of women in their reproductive years. During adolescence, transient cystic changes are quite commonly seen during adolescence ...
[9]
Anovulation: Signs, Symptoms, Causes & Treatment - Cleveland Clinic
Anovulation is a common condition and is the cause of approximately 30% of infertility cases. Symptoms and Causes. What are the signs and symptoms of ...
[10]
Female Infertility - StatPearls - NCBI Bookshelf - NIH
The most common type of Normogonadotropic normoestrogenic anovulation is PCOS. PCOS accounts for 80% to 85% of all anovulatory patients and affects 8% of all ...
[11]
Abnormal uterine bleeding in adolescents: causes, challenges and ...
Jan 31, 2023 · It is the most common gynaecologic complaint of adolescents admitted to a hospital, affecting up to 20% of reproductive-aged females, with a ...
[12]
Recognition of ovulatory/anovulatory cycle pattern in adolescents by ...
Ovulatory patterns were found at gynecologic ages of 1 year, 49%; 2 years, 60%; 3 years, 72%; 4 years, 61%; 5 years, 86%; and 6 years, 71%.Missing: prevalence | Show results with:prevalence
[13]
Adiposity is associated with anovulation independent of serum free ...
343 (28.3%) women experienced at least one anovulatory cycle. Anovulation risk was higher per kg/m2 greater BMI (relative risk [RR] 1.03, 95% confidence ...
[14]
Obesity and Female Infertility—A Review on Mechanisms ...
In a study of 2292 women, those with BMI ≥ 27 kg/m2 are found to be 3.1 times more likely to have ovulatory dysfunction as compared to their normal BMI ...
[15]
The Risks of Polycystic Ovary Syndrome and Diabetes Vary by ...
Jun 18, 2021 · Earlier PCOS presentation among South Asian women could contribute to the higher observed prevalence of PCOS in our study. Others have reported ...
[16]
Prevalence of polycystic ovarian syndrome in South Asian countries ...
Women from South Asian countries such as India, Pakistan, and Bangladesh appear to experience a higher prevalence of PCOS, with evidence indicating the syndrome ...<|separator|>
[17]
Worldwide trends in underweight and obesity from 1990 to 2022
Feb 29, 2024 · Obesity prevalence was higher than underweight with posterior probability of at least 0·80 in 177 countries (89%) for women and 145 (73%) for ...Missing: anovulation post-
[18]
Detecting variations in ovulation and menstruation during the COVID ...
Approximately 7.7% and 19.5% of users recorded more anovulatory cycles and abnormal cycle lengths during the pandemic, respectively. Contrary to expectation, ...
[19]
Age-Related Fertility Decline - StatPearls - NCBI Bookshelf
Feb 2, 2024 · Other contributing factors include changes in ovulation patterns with age, aging of the uterus, and increasing risks of complications.[5] The ...
[20]
The Influence of Diet on Ovulation Disorders in Women—A Narrative ...
Apr 8, 2022 · Another very important factor that increases the risk of ovulation disorders is oxidative stress and chronic inflammation [19]. High levels of ...
[21]
The Normal Menstrual Cycle and the Control of Ovulation - NCBI - NIH
Aug 5, 2018 · The menstrual cycle may be divided into two phases: (1) follicular or proliferative phase, and (2) the luteal or secretory phase.THE FOLLICULAR PHASE... · OVULATION · LUTEAL PHASE · MENSTRUATION
[22]
Physiology, Menstrual Cycle - StatPearls - NCBI Bookshelf
Sep 27, 2024 · Ovulation typically occurs 14 days before the onset of menses; thus, in an average 28-day cycle, ovulation occurs on day 14. Throughout the ...Introduction · Mechanism · Pathophysiology
[23]
Anovulation: Background, Pathophysiology, Etiology
Jan 6, 2023 · The incidence of POF has been estimated by Coulam in 1986 as 1 in 1,000 women younger than 30 years, and 1 in 100 women younger than 40 years.
[24]
Physiology, Ovulation - StatPearls - NCBI Bookshelf - NIH
Ovulation occurs around day 14 of a typical 28-day cycle. Estrogen levels rise as a result of increased estrogen production by hormonally active granulosa cells ...Introduction · Mechanism · Clinical Significance
[25]
Premature response to luteinizing hormone of granulosa cells from ...
Anovulation in polycystic ovary syndrome is characterized by the failure of selection of a dominant follicle with arrest of follicle development at the 5-10 mmMissing: central defects GnRH pulsatility peripheral surge feedback dysregulation insulin resistance AMH atresia<|control11|><|separator|>
[26]
Polycystic Ovary Syndrome: Pathophysiology, Presentation, and ...
Polycystic ovary syndrome (PCOS) is a heterogeneous disorder characterized by hyperandrogenism and chronic anovulation.<|control11|><|separator|>
[27]
Ovarian Follicle Atresia: A Hormonally Controlled Apoptotic Process
This review summarizes the historical background of studies on follicle atresia and selection as well as recent advances in the intraovarian hormonal mechanisms ...
[28]
The role of AMH in anovulation associated with PCOS: a hypothesis
In this article, it is hypothesized that the high AMH concentrations present in women with PCOS play an integral role in causing anovulation.
[29]
Anti-Müllerian Hormone: Its Role in Follicular Growth Initiation and ...
Mar 1, 2005 · AMH has an inhibitory effect on primordial follicle recruitment and may also inhibit follicle-stimulating homone–dependent selection of follicles for dominance.Abstract · INTRODUCTION · ANTI-MÜLLERIAN HORMONE
[30]
Anovulation - PMC - NIH
However, not all causes of anovulation are amenable to treatment by ovulation induction. Anovulation can sometimes be treated with medical or surgical ...
[31]
Menstrual Cramps in Anovulatory versus Normally Ovulatory Cycles
Jul 10, 2024 · This research studied 75 community women aged 19–35 years for a single cycle during COVID-19. Forty women had normally ovulatory cycles and ...
[32]
Mittelschmerz - Symptoms and causes - Mayo Clinic
Feb 13, 2024 · Mittelschmerz is one-sided, lower abdominal pain associated with ovulation. German for "middle pain," mittelschmerz occurs midway through a menstrual cycle.Missing: anovulation | Show results with:anovulation
[33]
Diagnosis and Management of Infertility: A Review - PubMed - NIH
Jul 6, 2021 · Ovulatory disorders account for approximately 25% of infertility diagnoses; 70% of women with anovulation have polycystic ovary syndrome.Missing: conditions | Show results with:conditions
[34]
Evaluation and management of abnormal uterine bleeding in ...
Jan 1, 2012 · Chronic anovulation can lead to irregular bleeding, prolonged unopposed estrogen stimulation of the endometrium, and increased risk of ...
[35]
Risk of type 2 diabetes mellitus in polycystic ovary syndrome is ...
Women with PCOS present an increased risk of T2DM compared with non-PCOS women only if they are obese/overweight.
[36]
The association between hyperandrogenemia and the metabolic ...
May 21, 2015 · Morbidly obese women with HA had an approximately 1.5-fold increased odds of having MetS even in the absence of PCOS.
[37]
Disturbances of menstruation in thyroid disease - PubMed
Jun 17, 1997 · Anovulation may be represent. Fertility is reduced in both hyper- and hypothyroidism, and the outcome of pregnancy is more often abnormal ...
[38]
Gynecologic and Obstetric Complications in Eating Disorders
Results: Malnutrition, low body weight are also an important cause of anovulation and amenorrhoea. Eating disorders such as anorexia nervosa, bulimia ...
[39]
Spinal bone loss and ovulatory disturbances - PubMed
Nov 1, 1990 · The 13 women who had anovulatory cycles lost bone mineral at a rate of 6.4 +/- 3.8 mg per cubic centimeter per year (4.2 percent per year). The ...Missing: hypoestrogenism | Show results with:hypoestrogenism
[40]
Polycystic ovary syndrome and cardiovascular disease - PubMed
There are studies that suggest a slight increase in cardiovascular events in women with polycystic ovaries, with perhaps stronger evidence between an increased ...
[41]
Polycystic ovary syndrome is associated with a higher risk ... - PubMed
Mar 24, 2023 · Conclusion: PCOS is associated with a higher risk of premalignant and malignant endometrial polyps in premenopausal women.
[42]
Hypothalamic-Pituitary-Ovarian Axis Disorders Impacting Female ...
Jan 4, 2019 · The ultimate goal for anovulation caused by eugonadal hypothalamic-pituitary dysfunction is to correct the underlying etiology. The majority of ...
[43]
The Female Athlete Triad: Recommendations for Management - AAFP
Apr 15, 2018 · Data show that 36% of female high school athletes have low energy availability, 19% to 54% have menstrual irregularity, and 13% to 19% have low ...
[44]
Dietary and Lifestyle Management of Functional Hypothalamic ...
Sep 3, 2024 · Three main factors are assumed to cause functional hypothalamic amenorrhea: psychological stress, caloric restriction, and excessive physical ...
[45]
Controversial issues in the management of hyperprolactinemia and ...
Prolactinomas are the most common pituitary adenomas (approximately 40% of cases), and they represent an important cause of hypogonadism and infertility in both ...
[46]
Sheehan Syndrome - StatPearls - NCBI Bookshelf - NIH
Chronic Sheehan syndrome is diagnosed due to symptoms that occur due to hypopituitarism, and again, it can occur months to years after the initial vascular ...
[47]
Kallmann Syndrome - StatPearls - NCBI Bookshelf - NIH
Kallmann syndrome is a rare congenital form of hypogonadotropic hypogonadism that manifests with partial or complete anosmia.[1] A deficiency in ...
[48]
Primary Ovarian Insufficiency - StatPearls - NCBI Bookshelf - NIH
Mar 6, 2023 · Primary ovarian insufficiency (POI) is a disease that affects women less than 40 years of age. Commonly, women present with amenorrhea for 4-6 ...Introduction · Etiology · Epidemiology · Evaluation
[49]
Congenital Adrenal Hyperplasia - StatPearls - NCBI Bookshelf - NIH
Jan 27, 2025 · The global incidence of classic 21-OH–deficient CAH is estimated to be 1 in 15,000 to 20,000 births in Western countries. Approximately 75% of ...
[50]
Resistant ovary syndrome: Pathogenesis and management strategies
Deficiency of follicle-stimulating growth factors, mutations in the follicle-stimulating hormone (FSH) receptor or beta subunit, abnormal gonadotropin signaling ...
[51]
Hyperprolactinemia - StatPearls - NCBI Bookshelf
Jul 24, 2023 · When the amount of serum prolactin exceeds the upper limit, we call it hyperprolactinemia. The common causes of hyperprolactinemia can be physiological, ...
[52]
Hyperprolactinemia and infertility: new insights - JCI
Sep 24, 2012 · Our studies demonstrated that hyperprolactinemia in mice induced anovulation, reduced GnRH and gonadotropin secretion, and diminished ...
[53]
Antipsychotic-induced hyperprolactinaemia: mechanisms ... - PubMed
During antipsychotic treatment prolactin levels can rise 10-fold or more above pretreatment values. In a recent study approximately 60% of women and 40% of men ...
[54]
Pharmacological treatment strategies for antipsychotic-induced ...
Jul 5, 2022 · Antipsychotic-induced hyperprolactinemia (AP-induced HPRL) occurs overall in up to 70% of patients with schizophrenia, which is associated ...
[55]
Thyroid dysfunction and subfertility - PMC - NIH
The prevalence of primary or secondary infertility associated with hyperthyroidism has been described to be 0.9% to 5.8% [6,7]. Nonetheless, the exact ...
[56]
Thyroid disease and female reproduction - ScienceDirect.com
Hyperthyroidism in women has been linked to reduced fertility, although most thyrotoxic women remain ovulatory according to the results of endometrial biopsies ...Modern Trends · Hyperthyroidism · Hypothyroidism
[57]
The Thyroid Hormone Axis and Female Reproduction - MDPI
Disruption of thyroid function has been linked to reproductive dysfunction in women and is associated with menstrual irregularity, infertility, poor pregnancy ...The Thyroid Hormone Axis And... · 3. Thyroid Hormones And... · 3.1. Thyroid Interface With...
[58]
Diagnosis and management of Cushing syndrome during pregnancy
Dec 18, 2023 · INTRODUCTION. Pregnancy is uncommon in women with Cushing syndrome as hypercortisolism typically results in anovulatory infertility.<|control11|><|separator|>
[59]
How do chemotherapeutic agents damage the ovary?
Meirow (2000) showed that alkylating agents caused ovarian failure in 42% of women treated, whilst those treated with platinum agents or plant alkaloids had no ...
[60]
Maximizing ovarian function and fertility following chemotherapy in ...
The risk of ovarian failure is the highest with alkylating agents (42.2 %), anthracyclines (<10–34 % in patients under 40 years versus 98 % in patients aged 40 ...
[61]
Cancer Treatment-Related Ovarian Dysfunction in Women of ...
Mar 8, 2023 · A CED ≥4,000 mg/m2 is associated with a significant risk of infertility. Among traditional chemotherapies, alkylating agents pose the highest ...
[62]
The direct effect of SARS-CoV-2 virus vaccination on human ovarian ...
Jun 26, 2024 · We aimed to unravel the direct effect of the COVID-19 vaccine on GCs and link their post-vaccine activity to changes in menstrual patterns.
[63]
Menstrual Changes Following COVID-19 Vaccination - NIH
Jan 25, 2024 · An association between menstrual changes and COVID-19 vaccines exists but has not been investigated in a rigorous or systematic manner.
[64]
Evaluation of Amenorrhea, Anovulation, and Abnormal Bleeding
Jan 15, 2018 · The “resistant ovary” syndrome may be the result of a gonadotropin postreceptor defect. As originally described, the Savage syndrome (named ...
[65]
Amenorrhea: A Systematic Approach to Diagnosis and Management
Jul 1, 2019 · The history should include menstrual onset and patterns, eating and exercise habits, presence of psychosocial stressors, body weight changes, ...
[66]
Hypothalamic Amenorrhea Guideline Resources - Endocrine Society
Mar 19, 2017 · Diagnostic options include physical examination, progestin challenge test, abdominal or transvaginal ultrasound, and/or MRI, depending on ...
[67]
Recommendations from the 2023 International Evidence-based ...
A comprehensive history and physical examination should be completed for symptoms and signs of clinical hyperandrogenism, including acne, female pattern ...
[68]
Anovulation Workup: Laboratory Studies, Imaging Studies, Procedures
Jan 6, 2023 · LH - In combination with FSH, helps establish a diagnosis of PCOS (with LH/FSH ratio >2:1). Ovarian steroid hormones - Estradiol, progesterone ( ...
[69]
Day 3 FSH Fertility Testing of Ovarian Reserve – Follicle Stimulating ...
Day 3 FSH blood test checks ovarian reserve – egg supply. There are better ovarian reserve tests, but day 3 FSH, LH and estradiol levels are commonly used.
[70]
Day 21 progesterone test - what does your level mean?
Oct 26, 2021 · If your level is below 3 ng/ml (9.54 nmol/L) this indicates that you probably haven't ovulated, at least not in THAT particular menstrual cycle.
[71]
Polycystic Ovary Syndrome - PCOS | Choose the Right Test
May 8, 2025 · Recommended laboratory testing for these conditions includes measurement of thyroid-stimulating hormone, prolactin, and serum 17- ...
[72]
505550: PCOS Diagnostic Profile - Labcorp
Guidelines also recommend excluding thyroid disease (TSH), prolactin excess (prolactin), and nonclassical congenital adrenal hyperplasia (17-OH progesterone) ...
[73]
PCOS Tests, Polycystic Ovarian Syndrome - Testing and Diagnosis
Laboratory testing for patients suspected of having PCOS: Serum testosterone; Prolactin; 17-OH progesterone, 17 hydroxyprogesterone, 17 OHP; LH, FSH, estradiol ...
[74]
Polycystic Ovarian Syndrome: Diagnosis and Management - PMC
In this proposal any one of four classic symptoms of PCOS (menstrual disturbance, hirsutism, acne or anovulatory infertility) should lead to an ultrasound ...
[75]
MR imaging of disorders associated with female infertility - PubMed
The applications of MR imaging include evaluation of the functioning uterus and ovaries, visualization of pituitary adenomas, differentiation of müllerian duct ...
[76]
Testing and interpreting measures of ovarian reserve: a ... - ASRM
Biochemical measures of ovarian reserve are intended to directly or indirectly measure the oocyte or follicular pool. Inhibin B and AMH are glycoprotein ...
[77]
Resumption of ovulation in anovulatory women with PCOS and ...
Mar 19, 2024 · Although the optimal degree of weight loss to restore ovulatory function is not clear, at least 5–10% weight loss is generally recommended ( ...
[78]
Impact of hypocaloric dietary intervention on ovulation in obese ...
Caloric restriction has been shown to promote sporadic ovulation in obese women with PCOS, but improvements have occurred across a wide range of patients.<|separator|>
[79]
Hypothalamic Amenorrhea: Causes, Symptoms & Treatment
Nov 10, 2022 · Lifestyle changes may include limiting vigorous exercise, gaining weight or finding ways to reduce stress levels. Your provider may recommend ...
[80]
https://pmc.ncbi.nlm.nih.gov/articles/PMC1069067/
[81]
Where Have the Periods Gone? The Evaluation and Management of ...
It is often seen in the setting of stress, weight loss, or excessive exercise. FHA is a diagnosis of exclusion.<|control11|><|separator|>
[82]
Can Diet Improve My PCOS? - Premom
Sep 8, 2022 · Studies have shown that following a low glycemic index diet improves regular ovulation in women with insulin resistance by 18% within just ...<|control11|><|separator|>
[83]
A randomized controlled trial comparing lifestyle intervention to ...
Nov 16, 2018 · One randomized controlled trial reported an ovulation rate of 70% when myo-inositol was given to women with PCOS versus a 21% ovulation rate in ...
[84]
Dose-response of acupuncture on ovulation rates in polycystic ovary ...
Aug 28, 2025 · The findings demonstrate that both acupuncture alone and acupuncture combined with pharmacotherapy significantly improve ovulation rates ...
[85]
Evaluating the equivalence of clomiphene citrate with and without ...
... anovulatory infertility. The treatment with C/C in anovulatory PCOS women is associated with an ovulation rate of 60–85% and a pregnancy rate of 30–40% [6].
[86]
Letrozole Compared With Clomiphene Citrate for Polycystic Ovarian ...
Mar 1, 2023 · Conclusions: Letrozole was associated with improved ovulation, pregnancy, and live-birth rates compared with clomiphene citrate. We recommend ...
[87]
Use of pulsatile gonadotropin-releasing hormone (GnRH) in patients ...
Nov 15, 2022 · The LBR per treatment was 65.9%. The ovulation rate per cycle was 96%, and monofollicular ovulation was observed in 75% of cycles. The BPR per ...
[88]
Use of exogenous gonadotropins for ovulation induction in ... - ASRM
Treatment of hypothalamic amenorrhea should include gonadotropin preparations with both FSH and LH activity to effectively stimulate steroidogenesis and ...
[89]
Hormone Therapy in Primary Ovarian Insufficiency - ACOG
In women with primary ovarian insufficiency, systemic hormone therapy (HT) is an effective approach to treat the symptoms of hypoestrogenism and mitigate long- ...
[90]
Evidence-based guideline: Premature Ovarian Insufficiency (2025)
Although hormone therapy (HT) can mitigate some of these effects, many questions still remain regarding the optimal management of POI. Study Design, Size, ...
[91]
Treatment of hyperprolactinemia in women: A Position Statement ...
Infertility treatment of patients with hyperprolactinemia is also carried out with dopamine agonists, aiming for the normalization of prolactin levels. The risk ...
[92]
In Vitro Fertilization Pregnancy Rates in Levothyroxine-Treated ... - NIH
Untreated hypothyroidism can lead to ovulatory dysfunction resulting in oligo-amenorrhea. Treatment with levothyroxine can reverse such dysfunction and thus ...
[93]
Hyperthyroidism: Diagnosis and Treatment - AAFP
Mar 1, 2016 · Thionamides can serve as a long-term therapy or as a bridge to I-131 ablation or thyroidectomy, with the goal of normalizing thyroid function ...
[94]
Chorionic Gonadotropin (Hcg) Dosage - Drugs.com
Sep 11, 2025 · Usual Adult Dose for Ovulation Induction. Human Chorionic Gonadotropin (HCG): 5000 to 10,000 units IM once 1 day following the last dose of ...Additional Dosage... · Dose Adjustments · Other Comments
[95]
Live Birth Rate in Patients With Premature Ovarian Insufficiency ...
Dec 16, 2021 · The LB rate per case in the patients in Group IVF-1-a with <4 years of amenorrhea was 37.3% (19/51), and that in the patients in Group IVF-2 ...Missing: anovulation | Show results with:anovulation
[96]
International evidence‐based guideline on assessment and ...
Nov 20, 2023 · The updated evidence-based guideline on assessment and management of polycystic ovary syndrome (PCOS) was released in August 2023, and is here summarized from ...
[97]
Premature Ovarian Insufficiency: Procreative Management and ... - NIH
Dec 28, 2018 · Pregnancy rate and live birth rates depend on the age of the oocyte donor. For women with iatrogenic POI due to cancer therapy, pregnancy rates ...
[98]
Adaptive, reversible, hypothalamic reproductive suppression
Over a mean follow-up of 8 years, 71% recovered menstrual cycling—74% on HRT, 80% who were untreated, and only 42% on CHC (49). The Endocrine Society's most ...
[99]
Premature Ovarian Insufficiency: Past, Present, and Future - PMC
May 10, 2021 · Premature ovarian insufficiency (POI) is the loss of normal ovarian function before the age of 40 years, a condition that affects approximately 1% of women ...Missing: anovulation | Show results with:anovulation
[100]
management of anovulatory infertility in women with polycystic ovary ...
Bariatric surgery is known to improve markers of PCOS influencing fertility, including anovulation, hirsutism, hormonal changes, IR, sexual activity and libido ...
[101]
Fertility Treatment Success Rates: IVF Insights by Age 2024
Aug 10, 2024 · Women aged 35 to 37 have about a 30% chance of success per cycle. By age 38, the success rate drops to around 20%. This trend continues as women get older.
[102]
Review Bariatric Surgery in Women with Polycystic Ovary Syndrome
In the first year after any surgical procedure, most women should lose enough weight to restart ovulation and to reduce the complications of a future pregnancy.
[103]
Clinical utility of FAI and SHBG in differentiating PCOS ... - Frontiers
Aug 7, 2025 · This study aims to establish diagnostic cut-off values for Polycystic Ovary Syndrome (PCOS) and differentiate it from anovulatory dysfunction in adolescents.
[104]
Are women with PCOS more at risk for endometrial cancer? What ...
The risk of endometrial cancer has been shown to be between 2 - 6 times higher in women with PCOS, with most adenocarcinomas (> 95%) including Type I and Type ...
[105]
Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary ...
Jul 2, 2020 · The most important mechanism by which PCOS increased the risk of endometrial cancer is the prolonged exposure of the endometrium to unopposed ...
[106]
Progesterone for the prevention and treatment of osteoporosis in ...
Meta-analysis shows that almost 1%/year spinal BMD loss occurs in those with greater than median (∼31%) of ovulatory disturbed cycles.Missing: hypoestrogenism | Show results with:hypoestrogenism
[107]
Spinal Bone Loss and Ovulatory Disturbances
Nov 1, 1990 · Osteoporosis develops in women with estrogen deficiency and amenorrhea who lose bone at an accelerated rate. It Is not known to what extent ...Missing: hypoestrogenism | Show results with:hypoestrogenism
[108]
The Role of Polycystic Ovary Syndrome in Reproductive and ...
May 1, 2015 · PCOS typically involves hormonal imbalances, insulin resistance, and metabolic abnormalities, which significantly increase the risk of infertility, type 2 ...
[109]
Polycystic ovary syndrome and cardiovascular risk - Oxford Academic
May 9, 2024 · Pooled analysis from 17 studies revealed that women with PCOS had a 1.51-fold higher risk of CVD (unadjusted) compared to women with no PCOS.Missing: anovulation | Show results with:anovulation
[110]
Prevalence of depression among women with polycystic ovary ...
Dec 18, 2024 · The prevalence of depression among women with PCOS is estimated to be 36%, significantly higher than in women without PCOS [12]. Due to the ...<|separator|>
[111]
Excess of severe autoimmune diseases in women with premature ...
Sep 25, 2024 · Women with POI had at least one hospital-treated autoimmune disorder preceding POI diagnosis 2.6 times more often compared with matched female controls.Missing: anovulation | Show results with:anovulation
[112]
Endometrial Cancer - AAFP
Jun 1, 1999 · Premenopausal patients with amenorrhea for more than six to 12 months should be offered endometrial sampling, especially if they have risk ...Missing: guideline | Show results with:guideline